BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 30044728)

  • 1. Challenges in Orphan Drug Development: Identification of Effective Therapy for Thyroid-Associated Ophthalmopathy.
    Smith TJ
    Annu Rev Pharmacol Toxicol; 2019 Jan; 59():129-148. PubMed ID: 30044728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin-Like Growth Factor Pathway and the Thyroid.
    Smith TJ
    Front Endocrinol (Lausanne); 2021; 12():653627. PubMed ID: 34149612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.
    Smith TJ; Janssen JAMJL
    Endocr Rev; 2019 Feb; 40(1):236-267. PubMed ID: 30215690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGF1 receptor and thyroid-associated ophthalmopathy.
    Mohyi M; Smith TJ
    J Mol Endocrinol; 2018 Jul; 61(1):T29-T43. PubMed ID: 29273685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The insulin-like growth factor-I receptor and its role in thyroid-associated ophthalmopathy.
    Smith TJ
    Eye (Lond); 2019 Feb; 33(2):200-205. PubMed ID: 30385883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy.
    Janssen JAMJL; Smith TJ
    Cells; 2021 Feb; 10(2):. PubMed ID: 33673340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor-1 enhances the expression of functional TSH receptor in orbital fibroblasts from thyroid-associated ophthalmopathy.
    Paik JS; Kim SE; Kim JH; Lee JY; Yang SW; Lee SB
    Immunobiology; 2020 Mar; 225(2):151902. PubMed ID: 31899052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TSHR as a therapeutic target in Graves' disease.
    Smith TJ
    Expert Opin Ther Targets; 2017 Apr; 21(4):427-432. PubMed ID: 28127991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy.
    Smith TJ; Hegedüs L; Douglas RS
    Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):291-302. PubMed ID: 22632366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
    Morshed SA; Ma R; Latif R; Davies TF
    Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy.
    Fernando R; Caldera O; Smith TJ
    Proc Natl Acad Sci U S A; 2021 Dec; 118(52):. PubMed ID: 34949642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orbital Signaling in Graves' Orbitopathy.
    Draman MS; Zhang L; Dayan C; Ludgate M
    Front Endocrinol (Lausanne); 2021; 12():739994. PubMed ID: 34899596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease.
    Girnita L; Smith TJ; Janssen JAMJL
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S1-S12. PubMed ID: 35167695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease.
    Tsui S; Naik V; Hoa N; Hwang CJ; Afifiyan NF; Sinha Hikim A; Gianoukakis AG; Douglas RS; Smith TJ
    J Immunol; 2008 Sep; 181(6):4397-405. PubMed ID: 18768899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrocyte Participation in Thyroid-Associated Ophthalmopathy Suggests New Approaches to Therapy.
    Smith TJ
    Ophthalmic Plast Reconstr Surg; 2023 Dec; 39(6S):S9-S18. PubMed ID: 38054981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teprotumumab: The Dawn of Therapies in Moderate-to-Severe Thyroid-Associated Ophthalmopathy.
    Ding Y; Yang S; Gao H
    Horm Metab Res; 2021 Apr; 53(4):211-218. PubMed ID: 33853117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
    Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
    Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy.
    Smith TJ; Janssen JA
    Front Endocrinol (Lausanne); 2016; 7():167. PubMed ID: 28096798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy.
    Smith TJ
    Nat Rev Endocrinol; 2015 Mar; 11(3):171-81. PubMed ID: 25560705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A human monoclonal autoantibody to the thyrotropin receptor with thyroid-stimulating blocking activity.
    Sanders J; Evans M; Betterle C; Sanders P; Bhardwaja A; Young S; Roberts E; Wilmot J; Richards T; Kiddie A; Small K; Platt H; Summerhayes S; Harris R; Reeve M; Coco G; Zanchetta R; Chen S; Furmaniak J; Smith BR
    Thyroid; 2008 Jul; 18(7):735-46. PubMed ID: 18631002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.